Aethlon Medical Reports Decreased Net Loss and Advances Oncology Clinical Trial in Australia

Aethlon Medical, Inc. reported its financial results for the three months ending June 30, 2026, revealing a net loss of $1.55 million, a decrease from a net loss of $1.76 million during the same period in 2025. The company's operating expenses also fell to $1.58 million, down 11.9% from $1.79 million year-over-year, primarily due to reduced professional fees and general administrative costs. The basic and diluted loss per share attributable to common stockholders was $(4.05), compared to $(4.24) in the prior year.

The company’s cash and cash equivalents stood at $4.93 million as of June 30, 2026, slightly down from $5.03 million at the end of the previous fiscal quarter. Aethlon Medical's working capital increased to $4.57 million, up from $4.12 million at March 31, 2026. The decrease in cash was attributed to net cash used in operating activities, which totaled approximately $1.90 million, compared to $1.71 million in the same quarter last year. The company generated approximately $1.82 million in net cash from financing activities, primarily from its at-the-market offering program.

In terms of strategic developments, Aethlon Medical is focused on advancing its Phase 1 oncology clinical trial in Australia, where it has treated the first participant in Cohort 3. The trial aims to evaluate the safety and feasibility of the Hemopurifier, an investigational device designed to treat various diseases, including cancer and life-threatening viral infections. The company has also published a manuscript on extracellular vesicle characteristics in patients with Long COVID, furthering its research initiatives.

Operationally, Aethlon Medical has made significant progress in its clinical trials, with ongoing patient enrollment at three sites in Australia. The company has discontinued its clinical trial program in India to conserve resources and concentrate on its Australian efforts. As of June 30, 2026, Aethlon Medical had 477,402 shares of common stock outstanding, reflecting an increase from 314,100 shares at the end of the previous quarter, following a successful equity issuance.

Looking ahead, Aethlon Medical anticipates that its current cash resources, along with proceeds from recent financing activities, will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the likelihood of needing additional capital to continue advancing the clinical development of the Hemopurifier beyond this period. Future capital requirements will depend on various factors, including the progress of clinical trials, regulatory activities, and operational expenditures.